http://oxfordpharmascience.com/


Oxford Pharmascience is a drug development company that re-develops approved drugs to make them better, safer and easier to take.

Oxford Pharmascience is using its proprietary oral drug delivery technologies to develop improved formulations of non-steroidal anti-inflammatory drugs (NSAIDs) and statins for global markets.

The Company's risk-diversified pipeline of prescription and OTC medicines is focused on cardiovascular disease and pain relief indications. Since the products incorporate previously approved drugs, this reduces risk and results in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market.

The Company has also commercialized calcium/vitamin D chews that taste better and dissolve faster than currently available regular formats. These products are now marketed in the UK, Middle East and Brazil.

Oxford Pharmascience is located in the UK and is led by a highly experienced management team that directs and manages the outsourcing of its development; pre-clinical and clinical programs; and manufacturing to a trusted network of partners and suppliers.

The Company commercializes its portfolio of product opportunities through out-licensing to leading pharmaceutical companies worldwide. Currently the Company has partnerships with Aché Laboratories and Bayer.

Oxford Pharmascience (LON:OXP) was established by a team of entrepreneurs in 2008 and is a publicly listed company on London's Alternative Investment Market (AIM), with a strong blue chip investor base.

OXPchew Feasibility and Option Agreement
RNS
RNS Number : 0340S
Oxford Pharmascience Group PLC
27 November 2012

Oxford Pharmascience Group plc

("Oxford Pharmascience")



Oxford Pharmascience announces OXPchew Feasibility and Option agreement with Major Healthcare Company

Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutical technologies to reformulate medicines, today announces it has signed a feasibility and option agreement with a major healthcare company ("The Company") to develop a dietary supplement product using OXP's chew technology for The Company.

Under the terms of the agreement, The Company has engaged Oxford Pharmascience to develop prototype products using its OXPchew technology and received an option to negotiate an exclusive licensing agreement to sell those products under its main multivitamin brand.

Nigel Theobald, Chief Executive, Oxford Pharmascience Group Plc, commented:

"This deal represents further progress in the development of our OXPchew business, which is now providing strong and growing revenue. We are making great progress in the £1bn global calcium market and this agreement provides the potential opportunity for us to enter the even larger £4bn+ multivitamin market, with a leading global Multivitamin brand.

We continue to show that our technologies once commercialised are capable of attracting some of the best healthcare companies worldwide as partners".

up 10%

OXPZero Feasibility and Option Agreement
RNS
RNS Number : 5004S
Oxford Pharmascience Group PLC
03 December 2012

Oxford Pharmascience Group plc ("Oxford Pharmascience")

OXPzeroTM Feasibility and Option agreement with Major Healthcare Company





Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reformulate medicines, today announces it has signed a feasibility and option agreement with a major healthcare company ("The Company"), to develop a range of undisclosed 'on the go' taste masked products.



Under the terms of the agreement, The Company has engaged Oxford Pharmascience to develop prototypes using its OXPzeroTM technology for a range of non tablet products that can be taken 'on the go' for inclusion in market research to determine the best products. Upon successful completion of the feasibility program, The Company will have an option for an exclusive worldwide license to sell the products under one of its main brands.





Nigel Theobald, Chief Executive, Oxford Pharmascience Group Plc, commented:



"This deal represents another major milestone in the commercialisation of our OXPzero technology."



Working with a leading global brand shows both credibility and potential. This is a very exciting deal for the future of our taste masking technology ".

For further information:

Oxford Pharmascience signs deal with ‘major healthcare company’ for taste-masking products
8:46 am by Jamie NimmoOXPzero allows acidic and anionic drugs to be administered orally without bad taste or irritation in non-tablet form and without affecting the drug's release in the body







Oxford Pharmascience (LON:OXP) has signed a feasibility and option agreement with a “major healthcare company” to develop a range of ‘on the go’ taste-masking products.

The pharmaceutical technology firm will develop prototypes using Oxford’s OXPzero platform to determine the best non-tablet products.

The company did not reveal the name of the partner firm but referred to it as a “major healthcare company”.

OXPzero allows acidic and anionic drugs to be administered orally without bad taste or irritation in non-tablet form. At the same time, however, it does not affect the drug’s release in the body.

“This deal represents another major milestone in the commercialisation of our OXPzero technology,” said Nigel Theobald, Oxford’s chief executive.

“Working with a leading global brand shows both credibility and potential. This is a very exciting deal for the future of our taste masking technology.”

Once the feasibility programme has been successfully completed, the healthcare company will have an option for an exclusive worldwide licence to sell the products under one of its main brands, Oxford said.

The news comes just a week after Oxford signed a similar deal with a “leading multivitamin brand” to develop a dietary supplement using the company's OXPchew technology.

Shares rose 0.15p or 8.8% to 1.85p.

Result of Meeting - Approval of Placing
RNS
RNS Number : 3489T
Oxford Pharmascience Group PLC
12 December 2012

Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company")

Result of General Meeting - Approval of Placing

Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reformulate medicines, announces that at its General Meeting held this morning at 10 a.m., the resolution was duly passed.

Accordingly, the conditional placing announced on 26 November, 2012 is now unconditional in all respects save for admission of the 153,846,154 new ordinary shares of 0.1 pence each. Admission is expected to take place at 8 a.m. on Thursday 13 December, 2012.

Following Admission, the Company will have 730,869,952 Ordinary Shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 730,869,952 and this figure may therefore be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

Nigel Theobald, CEO, commented:

"The Company looks forward to applying the proceeds from the placing to commercialising further its existing soft chew and taste-masking platforms, and to developing new applications including the colonic delivery statin products.

Oxford Pharmascience recently confirmed a feasibility and option agreement with a major healthcare company for a multivitamin supplement using OXPchew technology, and a similar type of agreement with another major to develop a range of 'on the go' non-tablet, taste masked products using OXPzero. The Company can therefore look forward to ongoing positive newsflow as it builds further shareholder value from its reformulation platform and know-how."

N+1 Singer sees Oxford Pharmascience (LON:OXP) as an appealing investment case thanks to its diversified technology platforms, strong IP protection and generic drugs dossier ownership.

The broker, which has a target price of 13.41p, believes Oxford is well placed for growth with significant opportunities in the pipeline.

investors who participated in the company’s £2mln fund-raising in November at 1.3p a share are sitting on a pretty profit, with the shares currently trading at around 2.2p


Top 10 Emerging Technology Company in 2012
RNS
RNS Number : 0467U
Oxford Pharmascience Group PLC
20 December 2012

Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company")

Named as Top Emerging Technology Company in 2012

Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reformulate medicines, has been featured in Lux Research's "Top Emerging Technology Companies in 2012".

Lux Research profiled 1,380 companies across 15 different emerging technology domains in 2012 and to conclude the year, selected the 10 most compelling companies they had profiled in 2012 across all its coverage areas, with Oxford Pharmascience making the top 10.



Nigel Theobald, CEO, commented:

"It is fantastic to be recognised in this way by such a respected research company as Lux.

We have invested in some exciting technologies for reformulating existing medicines and wholeheartedly agree that through our partnerships with major pharma companies we will indeed have some very compelling products to bring to market "

Moving up well

up 10.5%, Im a 100% upat 2.54p, in at 1.27p

Well done DreamCatcher!

Thanks Toya, OCG going well today as well. Did you grab a few ?

Bought in at 1.27, well up over 100% now, sold half on a free run now.

Time: (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above



Initial formulation development complete
RNS
RNS Number : 4192W
Oxford Pharmascience Group PLC
28 January 2013



Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience completes initial formulation development for leading statins



Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to make medicines better, safer and easier to take, today announces successful completion of formulation development for its Safestat™ formulations of Atorvastatin and Simvastatin, leading generic statin drugs.

The Company has already announced its Safestat™ program which aims to re-formulate the widely used molecules of atorvastatin and simvastatin into doses up to four times lower than the original dose but with the same lipid lowering efficacy as the original higher dose. Global revenue from statins in 2009 was over $27bn despite issues caused by side effects of statins leading to lack of compliance in patients taking these medicines. Safestat™ aims to overcome these issues and increase patient compliance for statins.

The Company has now developed and optimised formulations of both atorvastatin and simvastatin and proven in-vitro release under simulated human conditions.

Marcelo Bravo, Chief Technology Officer of Oxford Pharmascience commented,

"Completion of formulation development is a first important milestone in the Safestat™ programme and we are now ready to proceed to manufacture of GMP products for use in proof of concept clinical trials during 2013."



For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

N+1 Singer

Shaun Dobson/Jenny Wyllie +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc develops advanced yet practical pharmaceutical technologies to enable reformulation that adds value to off patent and soon to be off patent drugs. The Company does not manufacture or sell its own pharmaceutical products but instead seeks to license its technologies to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. These partners use our technologies to reposition their products helping them sustain market share and profitability by delivering improved health outcomes and/or clinical profiles via reformulated versions of the same API (active pharmaceutical ingredient).

Oxford Pharmascience Group Plc develops platform technologies that have application across multiple drug categories and can be leveraged across a broad range of reformulation problems. This business model allows us to provide solutions across the industry and fund the ongoing development of cutting edge technologies to better serve the needs of our partners. The partner companies who adopt our technology pay an up-front license fee followed by development milestone payments and then royalties on finished products sold using the technology. OXP invests the upfront licence fee to optimise product development and to ensure seamless technology transfer to the pharmaceutical partner.

House broker N+1 Singer has a positive view on Oxford Pharmascience’s (LON:OXP) pipeline of opportunities, and this morning’s news indicates it is moving ahead on plans to capitalise on those opportunities.

Shares in Oxford Pharmascience shot up 25% today after it successfully completed the formulation development for its Safestat formulations of Atorvastatin and Simvastatin, the leading generic statin drugs.

“Oxford Pharmascience continues to make progress in expanding into the larger generic drugs market, building on its niche position in the over the counter market, and this morning’s news validates this,” the broker said.

“The group was featured in Lux Research’s ‘Top Emerging Technology Companies in 2012’ based on its ability to manipulate properties to improve oral delivery of medicine,” the broker added.

Closed up 26%

Oxford Pharmascience in good heart after passing statin milestone
10:36 am by John Harrington “We’re looking to get into production in 2015," said CEO Nigel Theobald.

If you are one of the many people with high cholesterol who is unable to take medication to lower it because of unpleasant side effects, yesterday’s news from Oxford Pharmascience (LON:OXP) should get the pulse racing.

The group, which specialises in bringing out improved versions of off-patent and soon to be off-patent drugs, has completed the initial formulation development for its versions of generic cholesterol-lowering drugs, Atorvastatin and Simvastatin.

These two leading generic statins are widely prescribed by doctors to patients who have high cholesterol and for whom cholesterol reduction to a desirable level through a change of diet alone is insufficient.

One of the major problems with the statins, though, is that many users suffer unpleasant side effects such as inflammation and muscle damage.

A lower dosage would result in fewer side effects, but also, under normal circumstances, be less effective in lowering the patient’s cholesterol level.

However, Oxford Pharmascience’s Safestat development programme is working on a reformulation of atorvastatin and simvastatin to allow them to be accurately delivered to the colon where they are more effectively absorbed into the liver.

If you want to get “sciency” about it, the new formulation bypasses the gastro-intestinal tract, and this leads to higher levels of the drug reaching the liver, which is where all the cholesterol-inhibiting action goes on.

It’s this by-pass trick which means the same effect can be achieved at around a quarter of the dose, or at least it can under certain laboratory conditions.

As the company announcement put it, Oxford Pharmascience has “proven in-vitro release of its formulations under simulated human conditions.”

The statins market is a huge one, valued at more than US$29bn in 2009, but it could be a lot larger were it not for those pesky side effects.

Nigel Theobald, chief executive officer of Oxford Pharmascience, helpfully gave Proactive Investors an insight into how big the demand could be for its statin products.

“We usually quote figures from www.statinusage.com. Their survey reveals that nearly three-quarters of new users stop taking their statins by the end of the first year of use. Of those, 62% cite side effects as the reason for doing so,” Theobald said.

Oxford Pharmascience’s versions of statins would initially be ideal for “second line intervention” for cholesterol reduction, Theobald explained.

This is when the initial prescription of statins has not worked out, due to the aforementioned side effects.

Monday’s announcement was the first important milestone on the march to market – a march which might not be as long as you would expect, as Theobald explained.

“We’re looking to get into production in 2015. Now, two years might seem like a long time ahead to some, but in the drug development world it is short.

“By working with an existing drug with a proven safety record, we can get it to market a lot quicker and a lot cheaper.”

“We are very happy with the formulations in the lab. The next stage is to move on to manufacture the products to allow us to undertake proof of concept clinical trials this year.”

Theobald stressed that the manufacturing, under good manufacturing practice (GMP) conditions, is just for in-house testing purposes, as the company works to determine what levels of dosage are required to deliver required amounts of the statin to the liver.

Nevertheless, the 26% rise in the share price on Monday to 3.375p indicates that the first hurdle has been successfully negotiated; the shares are up another couple of per cent today.

Further down the road, the company will be looking at the possibility of bringing in a partner to help navigate the path to market.

Going great on this poor market day.

A three bagger at 3.81 :-))

Well done with this one dreamcatcher. I've just bought a few as I think the future is looking good.